Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from SAWAI GROUP HOLDINGS Co., Ltd. ( (JP:4887) ) is now available.
Sawai Group Holdings reported consolidated revenue of ¥154.9 billion for the nine months ended Dec. 31, 2025, up 8.1% year-on-year, but operating profit fell 25.7% to ¥15.9 billion and profit attributable to owners of the parent slumped 57.8% to ¥10.7 billion, reflecting weaker profitability despite topline growth. Total assets rose to ¥377.0 billion and equity attributable to owners reached ¥178.8 billion, while the company maintained its dividend outlook, targeting a total of ¥55 per share for the year ending March 31, 2026, and forecast full-year revenue of ¥202.5 billion and a sharp rebound in operating profit, signaling expectations of earnings recovery from its continued operations.
The dividend forecast for the full year remains unchanged.
The most recent analyst rating on (JP:4887) stock is a Hold with a Yen2567.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
More about SAWAI GROUP HOLDINGS Co., Ltd.
Sawai Group Holdings Co., Ltd. is a Japan-based pharmaceutical group listed on the Tokyo Stock Exchange, focused on the development, manufacturing and sale of generic drugs. The company serves the healthcare market with prescription medicines, and has recently designated its U.S. operations as a discontinued business to concentrate on its core domestic and continuing operations.
Average Trading Volume: 382,545
Technical Sentiment Signal: Buy
Current Market Cap: Yen238.7B
For a thorough assessment of 4887 stock, go to TipRanks’ Stock Analysis page.